Conferences archive > 2015 > SPEAKERS & ABSTRACTS

Guido Guidi

Guido Guidi is Head of Pharma Region Europe, Novartis.  In this position, he is responsible for leading Novartis’ General Medicines Business in the European Region, marketing several key products – Cosentyx, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge and others - and coordinating the Pharma operations of RE countries.

Guidi currently oversees a staff of more than 8,000 employees operating in more than 50 countries.  He is also a member of the Novartis Pharma Leadership Team (PLT) and Novartis Pharma Executive Committee (PEC). He has been instrumental in creating a visionary collaborative approach towards improving patient treatment in Europe, as well as a pioneer in leading Novartis towards a patient centricity approach through the implementation of “Winning for Patients” strategy.

Guidi covered different medical position at GSK and Roussel UCLAF; 1990, Medical Director LPB (Sandoz); subsequently joined Novartis; held several positions in general management then became Head Specialties in Italy; later, Head Region Europe South-Europe, Novartis Oncology, overseeing operations in 6 countries. Most recently he was the Head of Region Europe Oncology at Novartis

Guidi holds a degree cum laude in Medicine and Specialization in Immunology and Rheumatology, University of Milan (Italy). He completed various business courses at Harvard, Boston (USA) and IMD, Lausanne (Switzerland).

Guidi contributed to around 30 publications, mainly focusing on methodologies and management of clinical research. 

Guidi received a Business results Excellence Award relating to his period of leadership, from Novartis’ President and CEO, Daniel Vasella in 2006 and Talent Development Award in 2008.

Druggable Future: What it Takes and How We Can Get There

The confluence of genetic and genomic data and informatic capabilities open for an era in which it will be possible to define in a more adequate manner which patients are more likely to benefit from treatment with a given drug.
However, the case of Glivec development shows how, also in presence of a well-defined target, many practical hurdles slow down or put at risk the arrival of an effective treatment to patients.
Overcoming these hurdles open to a better understanding on how to optimize drug development and potentially reduce drug resistance.
The need for adequate markers to follow up the patients is also underlined stressing the importance of long term follow up.


torna top